Sarepta's gene therapy sales declined further, following its disappointing earnings report last month.[42397] Analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs, as the company seeks new opportunities.[42397] Meanwhile, Latus Therapeutics secured $97M in funding to pursue its own Huntington's gene therapy approach.[36410] The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses.[36410] This could enable them to be used against more than just ultra-rare conditions, according to Latus.[36410]